Susquehanna International Group, LLP I Mab Transaction History

Susquehanna International Group, LLP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$1.21 - $1.9 $25,172 - $39,527	-20,804 Reduced 41.47%	29,365 $55,000
Q3 2023 Nov 14, 2023	BUY	$1.18 - $3.06 $59,199 - $153,517	50,169 New	50,169 $66,000
Q3 2022 Nov 14, 2022	BUY	$4.01 - $12.34 $69,473 - $213,790	17,325 Added 102.91%	34,160 $137,000
Q2 2022 Aug 15, 2022	SELL	$8.27 - $18.43 $2,588 - $5,768	-313 Reduced 1.83%	16,835 $190,000
Q1 2022 May 16, 2022	BUY	$12.54 - $46.93 $154,919 - $579,773	12,354 Added 257.7%	17,148 $278,000

Q4 2021 Feb 14, 2022	BUY	$45.28 - $74.5 $59,226 - $97,446	1,308 Added 37.52%	4,794 $227,000
Q3 2021 Nov 15, 2021	SELL	$57.18 - $84.43 $428,792 - $633,140	-7,499 Reduced 68.27%	3,486 $253,000
Q2 2021 Aug 11, 2021	BUY	$47.86 - $83.95 $525,742 - $922,190	10,985 New	10,985 $922,000

16M

11.9K

3.5K

Ticker IMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,098,800
Market Cap $125M
Description
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.